A prospective comparative study of intravesical Bacillus Calmette-Guerin (BCG) therapy with the Tokyo or Connaught strains for non-muscle invasive bladder cancer

A prospective comparative study of intravesical Bacillus Calmette-Guerin (BCG) therapy with the Tokyo or Connaught strains for non-muscle invasive bladder cancer - Tokyo and Connaught BCG Strains for Bladder Cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009347

Enrollment

200

Registered

2012-11-16

Start date

2004-01-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder cancer

Interventions

the BCG Tokyo 172 strain group the BCG Connaught strain group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with pathological findings corresponding to stage Ta/T1 or Tis, multiple tumors, and a recurrence-free period of &#8804;3 months were eligible for intravesical BCG therapy.

Exclusion criteria

Exclusion criteria: Patients with a history of intravesical therapy or upper urinary tract tumor were excluded

Design outcomes

Primary

Measure	Time frame
Efficacy, side effects	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026